BITFURY GROUP LIMITED

1. Financial Health Score: B- (Incomplete Picture)

I am assigning a provisional score of B- because, while the patient is alive and exhibiting healthy regulatory vitals, we are operating with a severe blind spot regarding internal financial health. The corporate structure suggests this entity is likely a holding company or administrative vessel for the wider Bitfury Group. A low share capital of £25 is the financial equivalent of a very low blood pressure reading—it isn't fatal on its own, but it indicates that the real financial "blood flow" (capital and trading activity) is happening elsewhere in the corporate anatomy. Without detailed balance sheet and profit & loss figures, a higher score cannot be justified.

2. Key Vital Signs

• Compliance Pulse (Filing Status): Strong and Steady. The company’s accounts are up to date, with the last made-up date extending to June 2025, and the confirmation statement is filed with no overdue markers. This indicates a healthy, attentive administrative heartbeat with no symptoms of regulatory distress.
• Capital Blood Count (Share Capital): Dangerously Low Surface Reading. The issued share capital is a mere £25. For a global technology group, this is a minuscule figure. It strongly suggests this UK entity is not the primary trading "organ" but rather a dormant parent, a holding company, or an administrative shell. The real financial nutrients (cash, assets, revenue) are likely residing in subsidiary vessels.
• Nervous System Control (People with Significant Control): Highly Centralized. Valerijs Vavilovs holds the reins tightly, owning 25-50% of shares but commanding more than 75% of voting rights and holding the right to appoint/remove directors. This is a healthy sign if you value decisive, centralized leadership, but it creates a single point of failure. The company's strategic health is entirely dependent on this individual.
• Organ Function (Board of Directors): Robust but Complex. The board features eight directors of international nationality (American, Dutch, French, Georgian, Latvian). This indicates a high-functioning, globally experienced brain trust, though international boards can sometimes suffer from administrative friction or time-zone fatigue.

3. Diagnosis

Based on the available data, Bitfury Group Limited is in stable but opaque condition. The patient is not in administrative or liquidation distress; in fact, its regulatory vitals are excellent. However, the £25 share capital is a clear symptom that this specific legal entity is likely a holding vehicle rather than the operating engine of the Bitfury empire.

Because the financial data (turnover, fixed assets, net current assets) is omitted from the current file, we cannot measure the company's actual liquidity, profitability, or leverage. We can see the "skeleton" of the company—a well-structured, compliant, internationally governed entity with centralized founder control—but we cannot assess the "muscle" or "fat" without the detailed annual accounts. The lack of any overdue filings is an excellent sign, showing the company does not suffer from the administrative neglect that often precedes insolvency.

4. Recommendations

To improve financial wellness and gain a clearer picture of the patient's true health, the following actions are recommended:

1. Request Full Blood Work (Obtain Detailed Accounts): To move from a structural assessment to a true financial diagnosis, you must obtain the full filed accounts from Companies House. You need to examine the net current assets, net assets, and P&L reserves to ensure the UK entity isn't carrying hidden liabilities or suffering from anemia (negative equity).
2. Assess the Wider Circulatory System (Subsidiary Health): Because this is a "Group" category filing, the true health of the enterprise lies in its subsidiaries. Assess the financial health of the operating entities beneath this holding company to ensure the "blood supply" is reaching all parts of the organization.
3. Succession Planning for the Central Nervous System: Given the absolute control held by Valerijs Vavilovs, it is prudent to ensure there are robust contingency plans in place. Should the central figure become unavailable, the company must have mechanisms to prevent corporate paralysis.